<SEC-DOCUMENT>0000950170-25-019942.txt : 20250213
<SEC-HEADER>0000950170-25-019942.hdr.sgml : 20250213
<ACCEPTANCE-DATETIME>20250213163003
ACCESSION NUMBER:		0000950170-25-019942
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250213
DATE AS OF CHANGE:		20250213

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AN2 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001880438
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				820606654
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93617
		FILM NUMBER:		25620748

	BUSINESS ADDRESS:	
		STREET 1:		1800 EL CAMINO REAL, SUITE D
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94027
		BUSINESS PHONE:		(650) 331-9090

	MAIL ADDRESS:	
		STREET 1:		1800 EL CAMINO REAL, SUITE D
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94027

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Easom Eric
		CENTRAL INDEX KEY:			0001914503
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		171 FOREST LN.
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001193125-24-033944</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001914503</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.00001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001880438</issuerCik>
        <issuerName>AN2 Therapeutics, Inc.</issuerName>
        <issuerCusip>037326105</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">1800 El Camino Real</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite D</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Menlo Park</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">94027</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Eric Easom</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>1893132</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>1893132</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1893132</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>6.2</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>AN2 Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>1800 El Camino Real, Suite D, Menlo Park, CA 94027</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This statement is filed on behalf of Eric Easom (the "Reporting Person").</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The business address of the Reporting Person is c/o AN2 Therapeutics, Inc., 1800 El Camino Real, Suite D, Menlo Park, CA 94027.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>The Reporting Person is a citizen of the United States.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>The information contained on the cover page to this Schedule 13G is incorporated by reference into this Item 4.

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of December 31, 2024, based upon 29,878,890 shares of Common Stock outstanding as of November 6, 2024, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2024.

The Reporting Person is the beneficial owner of 1,893,132 shares of Common Stock, which consists of (i) 2,130 shares of Common Stock held directly by the Reporting Person, (ii) 1,259,882 shares of Common Stock held by various family trusts, over which the Reporting Person serves as trustee, (iii) 24,750 shares of Common Stock underlying restricted stock units that will vest within 60 days of December 31, 2024 and (iv) 606,370 shares of Common Stock underlying stock options that are vested or will vest within 60 days of December 31, 2024.</amountBeneficiallyOwned>
        <classPercent>6.2</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>1,893,132</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>1,893,132</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Eric Easom</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Eric Easom</signature>
        <title>Eric Easom</title>
        <date>02/13/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
